Dietary histone deactylase inhibitors in prostate cancer prevention
Dietary histone deactylase inhibitors in prostate cancer prevention
批准号:
8222022
负责人:
EMILY HO
金额:
$2.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-05-01 至 2013-02-28
关键词:
AccountingAcetylationAddressAdverse effectsAmericanAnimal ModelAntineoplastic AgentsAntioxidantsApoptosisBiological AvailabilityBiological MarkersBroccoli - dietaryCancer EtiologyCancer PatientCell Cycle ArrestCellsCessation of lifeChemopreventionChemopreventive AgentChemoprotective AgentClinicalClinical TrialsColorectal CancerConsumptionDevelopmentDiagnosisDietDietary InterventionEnzymesEpidemiologic MethodsEpidemiologic StudiesEpidemiologistEpigenetic ProcessEquilibriumEventFoodFoundationsFutureGene ExpressionGene Expression RegulationGlobal ChangeGoalsHealthHealth Care CostsHealthcareHistone AcetylationHistone DeacetylaseHistone Deacetylase InhibitorHistone H3Histone deacetylase inhibitionHistonesHistopathologyHumanImmunohistochemistryIncidenceInhibition of ApoptosisInjection of therapeutic agentIntakeInterventionIntervention StudiesIntervention TrialInvestigationIsothiocyanatesLinkMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMetabolismMethodsModelingModificationMolecularMorbidity - disease rateMusNormal CellNutritionalOutcomePathogenesisPathologistPathologyPathway interactionsPatientsPatternPharmaceutical PreparationsPhasePlayPopulationPopulation SciencesPopulations at RiskPrevention strategyProcessProstateProstatic NeoplasmsPublic HealthQualifyingQuality of lifeRecommendationReportingRepressionResearchResearch PersonnelResponse ElementsRiskRoleSignal PathwaySignal TransductionSmall Interfering RNASulforaphaneTechniquesTestingTimeTissuesTrainingTumor SuppressionUnited StatesUp-RegulationWorkbasecancer cellcancer chemopreventioncancer preventioncancer recurrencecancer riskcancer therapycostcruciferous vegetableevidence baseexperiencegene repressionhigh riskhigh risk menhistone acetyltransferasehistone modificationimprovedinhibitor/antagonistinnovationinsightinterestlifestyle factorsliquid chromatography mass spectrometrymalemenmortalitymouse modelnovelnovel strategiesperipheral bloodprogramsprostate cancer preventionprostate carcinogenesisprotective effecttranslational studytumortumor growthtumor progressionurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer is the most frequently diagnosed non-cutaneous cancer, and is the second leading cause of cancer death in American men. The precise etiologic factors that initiate and enhance the progression of prostate cancer remains unknown, but epigenetic alterations and diet/lifestyle factors have come forth as significant contributing factors. During prostate cancer, alterations in acetylation patterns and increases in histone deacetylases are apparent. The use of pharmacological agents that inhibit HDACs for cancer prevention and therapy have gained significant interest. HDAC inhibitors cause increases in acetylated histones, selectively induce cell cycle arrest and apoptosis in cancer cells and have shown promise in cancer clinical trials. We have recently reported that sulforaphane (SFN), a compound found in cruciferous vegetables, suppresses tumor growth in animal models and inhibits HDAC activity in prostate. Based on these findings we formulated the following central hypothesis: Sulforaphane acts as an inhibitor of HDAC in the prostate, resulting in the induction of histone acetylation and de-repression of genes such as p21 and Bax, contributing to cell cycle arrest and apoptosis, and thus cancer prevention. The long term goal of these studies is to determine the mechanisms by which cruciferous vegetables act to decrease prostate cancer risk. The objective of these studies is to identify novel prostate chemoprotective agents that act via HDAC inhibition and de-repression of gene expression leading to cancer prevention. Specifically, we propose to 1) Characterize the effects of dietary SFN on development of prostate cancer in a mouse for prostate carcinogenesis. The working hypothesis is that SFN treatment will suppress prostate tumor development in TRAMP mice. Suppression of tumor development will be associated with inhibition of HDAC activity, increases in the levels of acetylated histones and enhancement of apoptosis. 2) Examine the requirement of HDAC inhibition for SFN induced apoptosis and chemoprevention. The working hypothesis is that HDAC inhibition by SFN is a key mechanism leading to SFN-induced p21 and Bax expression and apoptosis.3) Examine in humans the effects dietary consumption of cruciferous vegetables on SFN metabolism, HDAC activity and acetylated histone status. The working hypothesis is that high cruciferous vegetable intake will be associated with lower HDAC activity in peripheral blood and increase acetylated histone levels in prostate tissue of men at high risk for prostate cancer.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/mnfr.201300210
发表时间:
2013-12
期刊:
MOLECULAR NUTRITION & FOOD RESEARCH
影响因子:
5.2
作者:
[Li, Yanyan, Zhang, Tao, Li, Xiaoqin, Zou, Peng, Schwartz, Steven J., Sun, Duxin]
通讯作者:
Sun, Duxin
Integrated Health Sciences Facilities Core
-
批准号:10383761
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Administrative Core
-
批准号:10207637
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Pacific Northwest Center for Translational Environmental Health Research
-
批准号:10383759
-
项目类别:
-
资助金额:$120.43万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Pacific Northwest Center for Translational Environmental Health Research
-
批准号:10207636
-
项目类别:
-
资助金额:$120.43万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Integrated Health Sciences Facilities Core
-
批准号:10207638
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Integrated Health Sciences Facilities Core
-
批准号:10602520
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2020
-
负责人:EMILY HO
-
依托单位:
Diet and arsenic interactions in the development of diabetes
-
批准号:8997082
-
项目类别:
-
资助金额:$18.35万
-
财政年份:2015
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7908175
-
项目类别:
-
资助金额:$29.48万
-
财政年份:2009
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7413331
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7777848
-
项目类别:
-
资助金额:$22.78万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:8021011
-
项目类别:
-
资助金额:$21.64万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7580931
-
项目类别:
-
资助金额:$27.87万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7256593
-
项目类别:
-
资助金额:$36.13万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:8032738
-
项目类别:
-
资助金额:$13.08万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Dietary histone deactylase inhibitors in prostate cancer prevention
-
批准号:7882730
-
项目类别:
-
资助金额:$11.23万
-
财政年份:2007
-
负责人:EMILY HO
-
依托单位:
Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation
-
批准号:8464015
-
项目类别:
-
资助金额:$71.4万
-
财政年份:2003
-
负责人:EMILY HO
-
依托单位:
Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation
-
批准号:8376149
-
项目类别:
-
资助金额:$75.06万
-
财政年份:2003
-
负责人:EMILY HO
-
依托单位:
Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation
-
批准号:7886289
-
项目类别:
-
资助金额:$67.67万
-
财政年份:2003
-
负责人:EMILY HO
-
依托单位:
Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation
-
批准号:8288251
-
项目类别:
-
资助金额:$58.18万
-
财政年份:2003
-
负责人:EMILY HO
-
依托单位:
Integrated Health Sciences Facilities Core
-
批准号:9918016
-
项目类别:
-
资助金额:$27.69万
-
财政年份:--
-
负责人:EMILY HO
-
依托单位:
海外基金